<b>Background:</b> Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an emerging class of glucose-lowering drugs that have become increasingly relevant for the treatment and prevention of heart failure (HF). The gene discussed is SLC5A2; the disease is heart failure.